Meeting News
Meeting News
Advertisement
Nichole TuckerAggressive B-Cell Lymphoma | January 3, 2025
Fludararabine lymphodepletion is more effective than bendamustine lymphodepletion, but more follow-up is needed to confirm.
Prithviraj Bose, MDMeeting News | December 30, 2024
The panel moderated by Prithviraj Bose, MD, goes into detail on practical aspects of this agent's use in the clinic.
Prithviraj Bose, MDMeeting News | December 30, 2024
The expert panel moderated by Dr. Bose looks at noteworthy study work on use of this agent for anemia in myelofibrosis.
Prithviraj Bose, MDMeeting News | December 30, 2024
Empaneled experts describe their investigations of momelotinib in a continued discussion moderated by Prithviraj Bose, MD.
Prithviraj Bose, MDMeeting News | December 30, 2024
The expert panel moderated by Prithviraj Bose, MD, tells which research presented at the Meeting they found most exciting.
Leah LawrenceMeeting News | December 27, 2024
According to a study, patients with MDS and CMML have dismal clinical outcomes after failure of HMA therapy.
Advertisement
Leah LawrenceMeeting News | December 27, 2024
Investigational combinations for MDS appeared to be well tolerated while triplets results in high-grade toxicity.
Leah LawrenceAcute Myeloid Leukemia | December 26, 2024
Phase 2 study results outline benefit of adding venetoclax to intensive chemo in MDS and AML patients.
Blood Cancers Today Staff WritersMeeting News | December 24, 2024
Moving forward, prospective studies must validate these findings and refine risk stratification tools like the IPSS-R in MDS.
Blood Cancers Today Staff WritersMeeting News | December 24, 2024
Outcomes for patients with AML and MDS who experience relapse after alloHSCT are poor.
Blood Cancers Today Staff WritersMeeting News | December 24, 2024
Overall, fedratinib 400 mg daily was a safe MTD for post-HSCT maintenance therapy for participants with MPN.
Blood Cancers Today Staff WritersMeeting News | December 24, 2024
Some patients with ZRSR2-mutated CCUS had concurrent blood cancers or disorders, and others had protective co-mutation.
Noa Biran, MDMeeting News | December 23, 2024
Noa Biran, MD reviews a clinical trial of SPd for relapsed or refractory multiple myeloma.
John Mascarenhas, MDMeeting News | December 26, 2024
Discussing current clinical trials iand unmet needs in myelofibrosis.
Patrick DalyAcute Myeloid Leukemia | December 23, 2024
Ziftomenib, venetoclax, and azacitadine is an close to an all-oral regimen for relapsed/refractory acute leukemias.
Patrick DalyAcute Myeloid Leukemia | December 23, 2024
The benefit of alternating venetoclax regimens was shown in patients with AML and certain AML subgroups.
Patrick DalyAcute Lymphoblastic Leukemia | December 23, 2024
Continued treatment and follow-up of patients after the interim analysis demonstrate the durability of response to revumenib.
Patrick DalyAcute Myeloid Leukemia | December 23, 2024
The confirmed complete response rate of ziftomenib with chemotherapy was high in patients with AML subtypes.
Nichole TuckerMantle Cell Lymphoma | December 20, 2024
Updated results from the phase 3 ECHO trial were presented at ASH 2024.
Nichole TuckerIndolent B-Cell Lymphoma | December 20, 2024
A new study aimed to confirm the possible synergy between loncastuximab and rituximab.
Advertisement
Advertisement
Editorial Board